Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IOV-2001 in relapsed/refractory CLL/SLL
NCT04155710Phase 1Completed
- Sponsor
- Iovance Biotherapeutics
- Start
- Feb 2020
- Primary completion
- Nov 2024
- Modality
- Native Immune Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of IOV-2001 in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (4 cohorts), sponsored by Iovance Biotherapeutics. Primary endpoints: Recommended Phase 2 Dose at 1 year and Objective Response Rate at 2 years. Started Feb 2020; status: completed.
02
Drugs
IOV-2001
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT04155710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04155710.